Please assess the completion status of the following clinical trial:

Trial Title: Intravitreal Ranibizumab Combined With Panretinal Photocoagulation in Patients With Proliferative Diabetic Retinopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Naive Proliferative diabetic retinopathy eyes.~* Best Corrected-Visual Acuity at baseline \> 20/320 in the study eye~* Patients with and without diabetic macular edema~* Type II diabetic subjects as defined by the World Health Organization aged ≥ 18 years.~* Women must be using effective contraception~* Ability to provide written informed consent.~* Indication of panretinal photocoagulation in both eyes~Exclusion Criteria:~* Vitreous hemorrhage or pre-retinal hemorrhage~* Eyes with prior scatter (panretinal) or focal/grid photocoagulation, within the previous 6 months~* Atrophy/scarring/fibrosis/ hard exudates involving the center of the macula.~* Cataract~* Any intraocular surgery within 6 months before trial enrollment~* Previous vitrectomy.~* Any of the following underlying systemic diseases:~* History or evidence of severe cardiac disease or previous thrombus-embolic event

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranibizumab (Type: EXPERIMENTAL): Ranibizumab 0,05 mg intravitreal injection
- Laser Therapy (Type: ACTIVE_COMPARATOR): Laser Therapy alone

Based on this trial design, predict the completion outcome and termination type (if applicable).